NLS Pharmaceutics AG
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of NLS Pharmaceutics AG generated cash of -$9,684,466, which is more than the previous year. Cash used in financing activities reached the amount of $1,633,746 last year. Net change in cash is therefore -$8,050,720.
Cash Flow
| 2017 | -5.43M | 0 | 6.72M |
|---|---|---|---|
| 2018 | -2.73M | 0 | 557.92K |
| 2019 | -190.00K | -217.25K | 407.47K |
| 2020 | -729.38K | 225.63K | 503.52K |
| 2021 | -14.93M | -39.56K | 20.33M |
| 2022 | -13.87M | -3.51M | 17.39M |
| 2023 | -9.68M | 0 | 1.63M |
NLSPW Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 8.94M | 5.43M | 93.71K | 220.26K | 6.67K | 2.18M | 882.76K |
Operating activities | |||||||
Net income | -12.17M | -16.49M | -11.94M | -2.86M | -5.44M | -5.14M | -6.65M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 11.40K | 11.40K | 10.05K | 72.18M | 0 | 0 | 0 |
Stock-based compensation expense | 164.90K | 22.73K | 0 | 0 | 0 | 0 | 77 |
| Deferred income tax benefit | 164.90K | 22.73K | 0 | 0 | 0 | 0 | 77 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | -21.80K | -13.48K | 1K | -41.10K | 44 |
Inventories | 0 | 0 | 0 | 0 | -7 | 41.10K | -44 |
Accounts payable | 2.26M | 636.26K | -2.26M | 1.49M | 1.37M | 565.85K | 350.02K |
Cash generated by operating activities | -9.68M | -13.87M | -14.93M | -729.38K | -190.00K | -2.73M | -5.43M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3 | 0 | -39.56K | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | -3.51M | -39.56K | 225.63K | -217.25K | 0 | 0 |
Financing activities | |||||||
Common Stock Issued | 0 | 9.21M | 18.89M | 0 | 0 | 0 | 3.27M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 1.63M | 825.84K | -2.10M | -1.19M | 154.89K | -557.92K | 3.45M |
Cash used in financing activities | 1.63M | 17.39M | 20.33M | 503.52K | 407.47K | 557.92K | 6.72M |
Net Change In Cash | -8.05M | 3.51M | 5.33M | -126.55K | 213.58K | -2.17M | 1.30M |
Cash at end of period | 897.68K | 8.94M | 5.43M | 93.71K | 220.26K | 6.67K | 2.18M |
| Data source | Data source | Data source | Data source |